OncoMatch/Clinical Trials/NCT05072314
Long-term Outcomes of Lidocaine Infusions for Post-Operative Pain (LOLIPOP) Trial
Is NCT05072314 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies lidocaine 2% and 10% for breast cancer.
Treatment: lidocaine 2% and 10% — The LOLIPOP Trial is a large (n=4,300 patients) pragmatic, international, multicentre, prospective, randomised, double blind, placebo-controlled, parallel assessment, safety and effectiveness superiority study.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Breast Carcinoma
Performance status
ASA 1–3
Demographics
Lab requirements
Kidney function
Severe Renal Failure (Creatinine Clearance of less than 30ml/min or dialysis dependent) [excluded]
Liver function
No active liver disease (e.g. viral hepatitis, alcoholic liver disease, non-alcoholic fatty liver disease, haemochromatosis, other rarer causes)
Cardiac function
No baseline heart rate < 50 bpm or systolic blood pressure < 100mmHg; no acute coronary event in last 3 months; no cardiac conduction abnormalities (Atrial fibrillation, Heart block, Bundle Branch Block, Fascicular block, Prolonged QT interval, Wolf Parkinson White syndrome, channelopathy such as Brugada syndrome); no cardiac failure
Baseline heart rate < 50 bpm or systolic blood pressure < 100mmHg. Acute coronary event in the last three months. Cardiac conduction abnormalities, including; Atrial fibrillation, Heart block (all degrees), Bundle Branch Block or Fascicular block, Prolonged QT interval, Wolf Parkinson White syndrome, channelopathy such as Brugada syndrome. Cardiac Failure (any documented heart failure at peroperative assessment or GP records). Active liver disease e.g. viral hepatitis, alcoholic liver disease, non-alcoholic fatty liver disease, haemochromatosis, other rarer causes). Severe Renal Failure (Creatinine Clearance of less than 30ml/min or dialysis dependent).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05072314 currently recruiting?
Yes, this trial is currently recruiting patients.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages